Seattle, WA -- (SBWIRE) -- 10/03/2019 -- Lyme disease is an infectious disease caused by Borrelia bacterium, which is spread through ticks. The most common symptoms of Lyme disease are headache, fever, fatigue, and skin rash called erythema migrans. If the infection is left untreated, it could spread to heart, nervous system, and joints. The first step of diagnostics is enzyme immunoassay (EIA). No additional treatment is required of the first screening is found to be negative. However, if the first step is positive, the second test is Western blot test. Moreover, results of the screening tests are considered positive only if both tests are positive. According to the Centers for Disease Control and Prevention (CDC), if the first screening is avoided, it will lead to false positive test and eventually to misdiagnosis and inadequate treatment. The Western blot test is the most precise antibody test, while ELISA tests are not sensitive enough for screening.

Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1608

Global Lyme Disease Diagnostics Market Dynamics

Lyme disease is an extremely difficult disease to detect as it can be confused with growing cases of tick-borne infectious disease and complexity and various symptoms in individual patient. Growing initiatives by the government on improvement of healthcare facilities and increasing prevalence of Lyme disease is expected to create lucrative environment of the key players in the market. According to the National Institute of Allergy and Infectious Diseases (NIAID) report, 2016, annually 300,000 cases of Lyme disease are recorded in the U.S. Several research institutes and government organizations are working on innovative novel diagnostic tests for Lyme disease. NIAID, in collaboration with CDC, plays a crucial role in encouraging development of new methods to improve Lyme disease screening. Moreover, NIAID grantees work in collaboration with CDC researchers to evaluate the efficacy of existing diagnostic methods.

Moreover, key players in the market are involved in research and development activities of new tests for Lyme disease diagnosis, which is expected to aid in growth of the global Lyme disease diagnostics market during the forecast period. For instance, in 2017, IGeneX Inc., a Clinical Laboratory Improvement Amendments (CLIA) and New York-approved Reference Laboratory, specializing in testing for tick-borne diseases— launched three new tests that are more comprehensive and specific for assisting in diagnosis of tick-borne relapsing fever and Lyme disease. However, lack of awareness about the disease and inadequacy in Lyme disease testing significantly hinders the market growth. Moreover, a lot of patients with Lyme-like symptoms are wrongly diagnosed as existing serological tests cannot accurately identify antibodies of all the different strains of B. burgdorferi. Therefore, demand for better diagnostic tests for the disease is increasing. Since the symptoms of tick-borne relapsing fever and Lyme are similar, development of more accurate test is required for proper diagnosis.

Global Lyme Disease Diagnostics Market Regional Insights

Regional segmentation of Lyme disease diagnostics market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global Lyme disease diagnostics market during the forecast period. This is owing to growing government initiatives for diagnosing and treatment of various diseases. Moreover, the Centers for Disease Control and Prevention (CDC) has increased their focus to develop novel strategies for prevention of Lyme disease, in order to reduce the prevalence of disease in the target populations. Moreover, growing pervasiveness of common tick disease in the region has led to high demand for effective disease treatment. According to a research paper, Lyme disease is the most prevalent tick-borne infection in North America and Europe. Moreover, it is the most vector borne disease in the U.S. so far. According to CDC, in 2015, Lyme disease was regarded as the sixth most-common infectious disease in the U.S. Europe Lyme disease diagnostics market is expected to exhibit high growth in the near future, owing to increasing prevalence of infected patients. The incidence of Lyme disease has been increasing significantly in some European countries. According to Center for Health Protection, Lyme disease cases in Europe are expanding with about 100 cases per 100,000 population every year.

Global Lyme Disease Diagnostics Market Competitive Analysis

Key companies involved in the Global Lyme disease diagnostics market include Abbott Laboratories, Affymetrix Inc., Alere Inc., Baxter International Inc., Bio-Rad Laboratories, Boulder Diagnostics, Canon Life Sciences, Covance Inc., Fresenius Medical Care AG & Co., GlaxoSmithKline Pharmaceuticals Ltd., Roche Diagnostics International Ltd., Siemens AG, and T2 Biosystems, Immunetics Inc. Key players in the market are focusing on developing new diagnostic tools, in collaboration with government organizations or research institutes or by themselves.

For More Details, Click @ https://www.coherentmarketinsights.com/ongoing-insight/lyme-disease-diagnostics-market-1608

Global Lyme Disease Diagnostics Market Taxonomy

On the basis of diagnostics test, the Global Lyme disease diagnostics market is segmented into:
- Enzyme Linked Immunosorbent Assay (ELISA)
- Western Blot
- Others

On the basis of end user, the Global Lyme disease diagnostics market is segmented into:
- Hospitals
- Clinics
- Diagnostic Laboratories

On the basis of region, the Global Lyme disease diagnostics market is segmented into:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa

Buy Now This Report @ https://www.coherentmarketinsights.com/insight/buy-now/1608

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.